INVO Fertility, Inc (NASDAQ:IVF) Sees Large Decrease in Short Interest

INVO Fertility, Inc (NASDAQ:IVF) saw a significant decrease in short interest in October. As of October 15th, there was short interest totaling 26,478 shares, a decrease of 47.2% from the September 30th total of 50,118 shares. Based on an average daily trading volume, of 140,470 shares, the short-interest ratio is currently 0.2 days. Approximately 1.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wall Street Zen upgraded shares of INVO Fertility to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, INVO Fertility currently has a consensus rating of “Moderate Buy” and an average target price of $320.00.

INVO Fertility Stock Down 10.9%

Shares of IVF stock traded down $0.23 during trading hours on Friday, hitting $1.91. 129,525 shares of the company’s stock traded hands, compared to its average volume of 114,523. The stock’s fifty day simple moving average is $13.26 and its two-hundred day simple moving average is $37.03. The stock has a market cap of $4.79 million, a price-to-earnings ratio of -0.06 and a beta of 2.39. INVO Fertility has a 12-month low of $1.59 and a 12-month high of $106.32. The company has a quick ratio of 0.67, a current ratio of 0.71 and a debt-to-equity ratio of 0.03.

INVO Fertility (NASDAQ:IVF) last released its earnings results on Friday, August 14th. The company reported $5.60 EPS for the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%. The business had revenue of $2.18 million for the quarter.

INVO Fertility Company Profile

INVO Fertility, Inc is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment.

Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.

In addition to commercializing INVOcell, INVO Fertility operates and supports fertility centers that provide reproductive services, including IVF and related treatments.